Apply for a Grant

If you are a researcher investigating on Down syndrome and other intellectual disabilities from genetic origin appearing in early childhood, the Scientific Advisory Board of the Jerome Lejeune Foundation invites you to submit research projects on patients with Down syndrome (Research on Down syndrome should globally represent more than 50% of the overall annual amount) or more basic research on human chromosome 21; or research on patients with rare intellectual deficit from genetic origin.


The calls for proposals have been changed!!

 Autumn calls for proposals will be exclusively dedicated to Down syndrome research;

 Spring calls for proposals will be dedicated to both Down syndrome and other rare intellectual disabilities from genetic origin such as Fragile X, cri du chat, Rett, Williams-Beuren, Prader-Willi, Angelman, Smith-Magenis and other syndromes, will not exceed 50% of the total amount of the annual global grant. Autism not linked to above diseases is out of this call for grants.

Both calls applications could cover fundamental, translational, epidemiological, clinical research, neurobiology, and pharmacology including animal pharmacology, genetic, genomic, iPSCs, and neuropsychology techniques or data analysis. Priority will be given to clinical research projects.

Two types of research projects may be submitted and will be separately evaluated by the scientific board experts or external reviewers if needed for each call:

• Pilot or exploratory grants will be dedicated to initial early stage experiments built on preliminary data, or to ancillary projects to primary larger projects. The maximum funding will be 40,000.00 € for a maximum of two years (i.e. 20,000.00 € per year for a maximum of two years. The number of funded projects will depend of the annual global budget allocated by the Jerome Lejeune Foundation to the calls. Clinical projects could benefit from more funding.

• Advanced grants will be dedicated to larger breakthrough projects with preliminary data. The maximum funding will be 80,000.00 € for a maximum of two years (i.e. 40,000.00 € per year for a maximum of two years. Two to four projects could be funded per call.

• Through this call the Jerome Lejeune Foundation will also support the organization of conferences, workshops and courses. Such projects will also be reviewed by the Scientific Advisory Board.

For further details, please click on SAMPLE below.



Autumn call: please fill in the online application form JLF Call for grants from 18 June to 6 August 2018 end of business day.

Date of provisional Scientific Advisory Board decision: mid-November 2018
Board of Directors final decision: December 2018


Conseil Scientifique – Fondation Jérôme Lejeune sample
37 rue des Volontaires, 75015 Paris, France
+33 (0)1 5658 5638



Les projets subventionnés par la Fondation Jérôme Lejeune

Session 2017b

15 projets subventionnés par la Fondation Jérôme Lejeune pour un montant de 510 513 €

France : 4 ; Italie : 5 ; Espagne : 1 ; Israël : 1 ; Royaume-Uni : 2 ; Etats-Unis : 2

Projets portant sur la Trisomie 21


• Prof. Alberto Costa
Preclinical assessment of short-term sensory memory deficits in mouse models of Down syndrome: evaluation of a mismatch negativity paradigm
The Research Institute for Children’s Health (RICH)
Case Western Reserve School of Medicine
Cleveland (Ohio), USA

• Dr. JM Delabar
Etude de l’efficacité d’un analogue de l’EGCG dans des modèles murins de trisomie 21
Institut du Cerveau et de la Moelle (Brain & Spine Institute)

• Dr. Sandra Guidi
Prenatal treatment with a BDNF mimetic: a potential strategy for improving brain development in the Ts65Dn mouse model of Down syndrome
University of Bologna
Department of Biomedical and Neuromotor Sciences (DIBINEM)

• Dr. Fernando Moldenhauer
Study of the renin-angiotensin-aldosterone system and its relation to the absence of atherosclerosis in adults with Down syndrome
Fundación de Investigació Biomédica Hospital de La Princesa
Unidad de Atención a Adultos con Sindrome de Down (MIH-UPDOWN)
Madrid, Spain

• Prof. Lucio Nitsch
Therapeutic approach in Down syndrome by PGC-1alpha activation in differentiating neural cells
University of Naples Federico II
Laboratory of Cytogenetics and Cytogenomics
Department of Molecular Medicine and Medical Biotechnology

• Dr. Nicoletta Pedemonte
A drug repositioning approach for the discovery of DYRK1A regulators as a therapy for Down syndrome
Istituto di Ricovero e Cura a Carattere Scientifico « Giannina Gaslini »
Genova, Italy

• Prof. Mary Rutherford
Serial MRI to assess early structural and functional brain development in Down syndrome
Centre for Developing Brain
Department of Perinatal Imaging and Health
Kings’ College London, United-Kingdom


Autres pathologies (syndromes tels que l’X fragile; Williams-Beuren; DiGeorge; Cri du chat…)

• Prof. Lior Appelbaum
The Allan-Herndon-Dudley syndrome: Visualizing deficient neuronal activity and examination of therapeutic applications
Bar Ilan University
Faculty of Life Sciences
Multidisciplinary Brain Research Center
Ramat Gan, Israel

• Dr. J.-V. Barnier
Caractérisation d’une nouvelle mutation d’un gène de déficience intellectuelle dans des anomalies neurodéveloppementales
Institut de Neuroscience Paris-Saclay, France

• Dr. Régine Hepp
Molecular mechanisms of a disease-causing missense mutation in the GRID1 gene associated with autosomal recessive intellectual disability
Université Pierre et Marie Curie
Institut de Biologie Paris-Seine
CNRS UMR8246/Inserm U1130/UPMC UMCR18
Paris, France

• Prof. Elizabeth Illingworth
Vitamin B12 treatment of mouse models of DiGeorge syndrome: is it effective for the brain phenotype?
Universita’ degli Studi di Salerno
Dipartimento di Chimica e Biologia
Fisciano, Italy

• Dr. Seonil Kim
Treatment of mental retardation and autistic-like characteristics in Cri du chat syndrome arising from delta-catenin haploinsufficiency
Colorado State University
Department of Biomedical Sciences
Fort Collins, USA

• Dr. Natacha Lehman
Thérapie Cognitive et Comportementale de l’anxiété dans le syndrome de Williams-Beuren
CHU Montpellier

• Dr. Viviana Trezza
The endocannabinoid system as a novel therapeutic target for Fragile X syndrome
Roma Tre University
Department of Science
Roma, Italy

• Dr. Jane Waite
Ten-year longitudinal follow-up of people with Rubinstein-Taybi syndrome: Predicting Mental Health outcomes
Aston University
School of Life and Health Sciences
Birmingham, United-Kingdom

Chère future Maman

Voir d’autres vidéos

Newsletter mensuelle

Institut Jérôme Lejeune